Lead Product(s) : Vebreltinib,Osimertinib Mesylate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : LaunXP Biomedical
Deal Size : $60.0 million
Deal Type : Agreement
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
Details : under the agreement, LaunXP receives exclusive development and commercialization rights for APL-101 (vebreltinib) in combination with an EGFR inhibitor for the treatment of non-small cell lung cancer.
Product Name : APL-101
Product Type : Other Small Molecule
Upfront Cash : $10.0 million
March 31, 2025
Lead Product(s) : Vebreltinib,Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : LaunXP Biomedical
Deal Size : $60.0 million
Deal Type : Agreement
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Apollomics Announces Positive Data for Vebreltinib in MET Fusion Tumors in Phase 2
Details : APL-101 (vebreltinib) is a small-molecule inhibitor that targets MET tyrosine kinase activity. It is being developed for the treatment of MET Exon 14 skip non-small cell lung cancer.
Product Name : APL-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 13, 2024
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Canaccord Genuity
Deal Size : $6.0 million
Deal Type : Private Placement
Apollomics Announces Private Placement Financing and Addition to Board of Directors
Details : Apollomics plans to use proceeds to fund pipeline programs including APL-101, a selective c-Met inhibitor, for treating non-small cell lung cancer and tumors with c-Met alterations.
Product Name : APL-101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 05, 2024
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Canaccord Genuity
Deal Size : $6.0 million
Deal Type : Private Placement
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Apollomics Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Predicine Collaborates with Apollomics for Lung Cancer Companion Diagnostic
Details : The collaboration seeks to develop PredicineCARE, a blood cfDNA NGS assay to identify NSCLC patients who may benefit from therapy with APL-101 (vebreltinib), a small molecule c-Met inhibitor.
Product Name : APL-101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 04, 2024
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Apollomics Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Avistone Approves Vebreltinib as First MET-TKI Treatment for Rare Glioma Subtype in China
Details :
Product Name : PLB1001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 25, 2024
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : SDIC CS Capital
Deal Size : $140.0 million
Deal Type : Series B Financing
Avistone Biotechnology Announces Closing of Series B Financing
Details :
Product Name : PLB1001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 01, 2024
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : SDIC CS Capital
Deal Size : $140.0 million
Deal Type : Series B Financing
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : APL-101 (vebreltinib) is a small-molecule inhibitor that targets MET tyrosine kinase activity. It is being developed for the treatment of MET Exon 14 skip non-small cell lung cancer.
Product Name : APL-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 16, 2023
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : APL-101 (vebreltinib) is a highly specific cMet inhibitor which is under phase 2 clinical development in non-small cell lung cancer and other solid tumors with MET dysregulations.
Product Name : APL-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 31, 2023
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Maxpro Capital Acquisition Corp.
Deal Size : $23.6 million
Deal Type : Private Placement
Details : Apollomics will use the financing to advance APL-101 (vebreltinib), a highly specific cMet inhibitor, in non-small cell lung cancer and other solid tumors with cMet dysregulation.
Product Name : APL-101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 30, 2023
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Maxpro Capital Acquisition Corp.
Deal Size : $23.6 million
Deal Type : Private Placement
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Ping An Capital
Deal Size : $124.0 million
Deal Type : Series C Financing
Apollomics, Inc. Closes $124 Million Series C Financing
Details : Proceeds from the Series C financing will support the development of the Apollomics pipeline with a focus on the Company’s lead programs: APL-101 and APL-106.
Product Name : APL-101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 11, 2020
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Ping An Capital
Deal Size : $124.0 million
Deal Type : Series C Financing